Rivaroxaban: latest news - GoINPHARMA
Friday, 16 November 2018 - 19:16

Rivaroxaban

Xarelto significantly reduces major cardiovascular events

Results from the Phase III COMPASS study found that Xarelto (rivaroxaban) 2.5 mg twice daily, plus aspirin 100 mg once daily, significantly reduced the risk of major cardiovascular events: the rate of CV death, heart attack or stroke decreased by…

FDA, no problems in ROCKET-AF trial for Xarelto

In July 2016, result accuracy problems were detected for the Alere INRatio device. This device was used to monitor warfarin therapy in the control group of the ROCKET-AF clinical trial, whose results supported the 2011 approval of Bayer’s Xarelto (rivaroxaban)….